Literature DB >> 25652820

How we handled the dextran shortage: an alternative washing or dilution solution for cord blood infusions.

Ronit Reich-Slotky1, Lohith S Bachegowda1,2, Michael Ancharski1, Lyubov Mendeleyeva1, Pablo Rubinstein2, Hanna Rennert3, Tsiporah Shore4, Koen van Besien4, Melissa Cushing1,3.   

Abstract

Dextran 40 is the main component of the solution used to wash or dilute thawed cord blood unit (CBU) products for stem cell transplant. Dextran 40 became unavailable in the United States as of April 2014. Like many other cellular therapy laboratories in the United States, we found ourselves with limited dextran 40 inventory, a growing CBU transplant requirement, and no alternative solution. Since there are no published alternative washing solutions for cryopreserved CBU we had to develop and validate a new solution rapidly. We chose to validate hydroxyethyl starch (HES) due to its similar ability to stabilize red blood cells and reduce sudden changes in osmolality that occur during thawing. For the validation we used 3 CBUs and thawed and washed each unit with both dextran 40- and HES-based solutions; thus, each CBU served as its own control. We observed no significant differences between the two wash solutions for all the monitored variables including cell viability, cell recovery, or potency measured by colony-forming cell assay. Based on this initial validation we began using HES-albumin for CBU washing after our supply was exhausted. Our initial experience with the first 16 CBU transplants after validation indicates safe infusion and preliminary cord engraftment.
© 2015 AABB.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25652820     DOI: 10.1111/trf.13015

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  1 in total

1.  A severe umbilical cord stem cell infusion reaction due to dextran in an atopic pediatric patient.

Authors:  L Cooling; A Sankar; R Mody; G Yanik; C Bonifant; S W Choi
Journal:  Bone Marrow Transplant       Date:  2017-03-06       Impact factor: 5.483

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.